Literature DB >> 26018615

Balancing the basal ganglia circuitry: a possible new role for dopamine D2 receptors in health and disease.

Maxime Cazorla1,2,3, Un Jung Kang4, Christoph Kellendonk1,2,3.   

Abstract

Current therapies for treating movement disorders such as Parkinson's disease are effective but limited by undesirable and intractable side effects. Developing more effective therapies will require better understanding of what causes basal ganglia dysregulation and why medication-induced side effects develop. Although basal ganglia have been extensively studied in the last decades, its circuit anatomy is very complex, and significant controversy exists as to how the interplay of different basal ganglia nuclei process motor information and output. We have recently identified the importance of an underappreciated collateral projection that bridges the striatal output direct pathway with the indirect pathway. These bridging collaterals are extremely plastic in the adult brain and are involved in the regulation of motor balance. Our findings add a new angle to the classical model of basal ganglia circuitry that could be exploited for the development of new therapies against movement disorders. In this Scientific Perspective, we describe the function of bridging collaterals and other recent discoveries that challenge the simplicity of the classical basal ganglia circuit model. We then discuss the potential implication of bridging collaterals in the pathophysiology of Parkinson's disease and schizophrenia. Because dopamine D2 receptors and striatal neuron excitability have been found to regulate the density of bridging collaterals, we propose that targeting these projections downstream of D2 receptors could be a possible strategy for the treatment of basal ganglia disorders.
© 2015 International Parkinson and Movement Disorder Society. © 2015 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Dopamine receptors; Parkinson's disease; bridging collaterals; direct and indirect pathways; dyskinesia

Mesh:

Substances:

Year:  2015        PMID: 26018615      PMCID: PMC4913465          DOI: 10.1002/mds.26282

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  56 in total

1.  Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry.

Authors:  Alexxai V Kravitz; Benjamin S Freeze; Philip R L Parker; Kenneth Kay; Myo T Thwin; Karl Deisseroth; Anatol C Kreitzer
Journal:  Nature       Date:  2010-07-07       Impact factor: 49.962

2.  Distinct roles of synaptic transmission in direct and indirect striatal pathways to reward and aversive behavior.

Authors:  Takatoshi Hikida; Kensuke Kimura; Norio Wada; Kazuo Funabiki; Shigetada Nakanishi
Journal:  Neuron       Date:  2010-06-24       Impact factor: 17.173

3.  Effects of acute dopamine depletion on the electrophysiological properties of striatal neurons.

Authors:  Elodie Fino; Jacques Glowinski; Laurent Venance
Journal:  Neurosci Res       Date:  2007-04-07       Impact factor: 3.304

4.  Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease.

Authors:  T H McNeill; S A Brown; J A Rafols; I Shoulson
Journal:  Brain Res       Date:  1988-07-05       Impact factor: 3.252

5.  Striatal D2 receptors regulate dendritic morphology of medium spiny neurons via Kir2 channels.

Authors:  Maxime Cazorla; Mariya Shegda; Bhavani Ramesh; Neil L Harrison; Christoph Kellendonk
Journal:  J Neurosci       Date:  2012-02-15       Impact factor: 6.167

6.  Single striatofugal axons arborizing in both pallidal segments and in the substantia nigra in primates.

Authors:  A Parent; A Charara; D Pinault
Journal:  Brain Res       Date:  1995-11-06       Impact factor: 3.252

7.  Cortical slow oscillatory activity is reflected in the membrane potential and spike trains of striatal neurons in rats with chronic nigrostriatal lesions.

Authors:  K Y Tseng; F Kasanetz; L Kargieman; L A Riquelme; M G Murer
Journal:  J Neurosci       Date:  2001-08-15       Impact factor: 6.167

8.  Dopamine D2 receptors regulate collateral inhibition between striatal medium spiny neurons.

Authors:  Rupa R Lalchandani; Marie-Sophie van der Goes; John G Partridge; Stefano Vicini
Journal:  J Neurosci       Date:  2013-08-28       Impact factor: 6.167

9.  Baseline and amphetamine-stimulated dopamine activity are related in drug-naïve schizophrenic subjects.

Authors:  Anissa Abi-Dargham; Elsmarieke van de Giessen; Mark Slifstein; Lawrence S Kegeles; Marc Laruelle
Journal:  Biol Psychiatry       Date:  2009-01-23       Impact factor: 13.382

10.  Neuronal activity is required for the development of specific cortical interneuron subtypes.

Authors:  Natalia V De Marco García; Theofanis Karayannis; Gord Fishell
Journal:  Nature       Date:  2011-04-03       Impact factor: 69.504

View more
  22 in total

Review 1.  The external globus pallidus: progress and perspectives.

Authors:  Daniel J Hegeman; Ellie S Hong; Vivian M Hernández; C Savio Chan
Journal:  Eur J Neurosci       Date:  2016-03-28       Impact factor: 3.386

Review 2.  Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.

Authors:  Delphine Charvin; Rossella Medori; Robert A Hauser; Olivier Rascol
Journal:  Nat Rev Drug Discov       Date:  2018-09-28       Impact factor: 84.694

3.  Impairment in subcortical suppression in schizophrenia: Evidence from the fBIRN Oddball Task.

Authors:  Katie M Lavigne; Mahesh Menon; Todd S Woodward
Journal:  Hum Brain Mapp       Date:  2016-08-01       Impact factor: 5.038

4.  Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators.

Authors:  Samantha E Yohn; Daniel J Foster; Dan P Covey; Mark S Moehle; Jordan Galbraith; Pedro M Garcia-Barrantes; Hyekyung P Cho; Michael Bubser; Anna L Blobaum; Max E Joffe; Joseph F Cheer; Carrie K Jones; Craig W Lindsley; P Jeffrey Conn
Journal:  Mol Psychiatry       Date:  2018-08-16       Impact factor: 15.992

5.  Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.

Authors:  Xiomara A Perez; Danhui Zhang; Tanuja Bordia; Maryka Quik
Journal:  Mov Disord       Date:  2017-03-03       Impact factor: 10.338

6.  Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy.

Authors:  Cristina Alcacer; Laura Andreoli; Irene Sebastianutto; Johan Jakobsson; Tim Fieblinger; Maria Angela Cenci
Journal:  J Clin Invest       Date:  2017-01-23       Impact factor: 14.808

Review 7.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

8.  Reduction of repetitive behavior by co-administration of adenosine receptor agonists in C58 mice.

Authors:  Mark H Lewis; Hemangi Rajpal; Amber M Muehlmann
Journal:  Pharmacol Biochem Behav       Date:  2019-05-02       Impact factor: 3.533

9.  Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson's disease.

Authors:  Andrea Herrera; Patricia Muñoz; Irmgard Paris; Gabriela Díaz-Veliz; Sergio Mora; Jose Inzunza; Kjell Hultenby; Cesar Cardenas; Fabián Jaña; Rita Raisman-Vozari; Katia Gysling; Jorge Abarca; Harry W M Steinbusch; Juan Segura-Aguilar
Journal:  Cell Mol Life Sci       Date:  2016-03-21       Impact factor: 9.261

Review 10.  Striatal Local Circuitry: A New Framework for Lateral Inhibition.

Authors:  Dennis A Burke; Horacio G Rotstein; Veronica A Alvarez
Journal:  Neuron       Date:  2017-10-11       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.